All In Biotech

NDA 021264 · Mdd US

Apokyn

Apomorphine Hydrochloride · Subcutaneous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Apr 20, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

51

19 Phase 3, 4 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 16, 2017 Supplement 14 · Efficacy OrphanLabelLetter
  • Apr 20, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
2 products under this application
  • APOKYN · APOMORPHINE HYDROCHLORIDE 20MG/2ML (10MG/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
  • APOKYN · APOMORPHINE HYDROCHLORIDE 30MG/3ML (10MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Apomorphine" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Apokyn (Apomorphine HCl)

2024 spending

$70.4M

Beneficiaries

592

2,414 claims

Per beneficiary

$118,900

$486.69 per unit

View as table
YearSpending
2020$107,272,823
2021$91,670,090
2022$69,087,700
2023$71,778,607
2024$70,388,816

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 313 on PubMed

Sponsor: Mdd US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.